Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Naltrexone × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4 Other 2 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Glioma 1 Glioblastoma 1

Interventions

Temozolomide 517 Radiotherapy 327 Bevacizumab 214 Magnetic Resonance Spectroscopy 172 Cyclophosphamide 146 Carboplatin 133 Radiosurgery 131 Etoposide 109 Radiation 99 Irinotecan 97 Vincristine 90 Cisplatin 81 Filgrastim 80 pembrolizumab 74 Specimen Handling 73 Nivolumab 71 Lomustine 71 Surgical Procedures, Operative 58 Topotecan 57 Melphalan 50 Carmustine 49 Radiotherapy, Intensity-Modulated 45 Doxorubicin 45 sargramostim 44 Granulocyte Colony-Stimulating Factor 44 Peripheral Blood Stem Cell Transplantation 43 Isotretinoin 41 Erlotinib Hydrochloride 40 Chemotherapy, Adjuvant 40 Granulocyte-Macrophage Colony-Stimulating Factor 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡